BSX
A tiny haircut, not a buzzcut
Truist Financial took a pair of scissors to Boston Scientific’s price target, cutting it from $92 to $90. But before you start thinking the analyst desk went full doom-and-gloom, the firm kept its Buy rating on the stock. So this was more “trim the bangs” than “shave the head.”
Why investors should care
A lower target can nudge sentiment, but the real message here is that Truist still sees upside from here. With the new target implying roughly 38.6% upside from the prior close, the note says Boston Scientific remains a name the Street wants to own, just with slightly less runway than before.
The numbers under the hood
The note lands right as Boston Scientific is coming off a quarter that looked pretty solid: EPS came in at $0.80 versus $0.78 expected, and revenue hit $5.29 billion, right in line with estimates. That’s the kind of results sheet that keeps analysts from reaching for the panic button.
Big picture
For you, this is less about a dramatic reset and more about the market’s favorite sport: fine-tuning expectations. Boston Scientific still has Wall Street support, but the stock may now need to keep delivering on earnings and growth to justify the praise. Big picture: the bull case is alive — it just got slightly less caffeinated.